Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
References
1. Platt, F.M., Neises, G.R., Karlsson, G.B., et al. N-Butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. J. Biol. Chem 269(43), 27108-27114 (1994).|2. Walden, C.M., Sandhoff, R., Chuang, C.C., et al. Accumulation of glucosylceramide in murine testis, caused by inhibition of β-glucosidase 2: implications for spermatogenesis. J. Biol. Chem. 282(45), 32655-32664 (2007).|3. Ridley, C.M., Thur, K.E., Shanahan, J., et al. β-Glucosidase 2 (GBA2) activity and imino sugar pharmacology. J. Biol. Chem. 288(36), 26052-26066 (2013).|4. Wennekes, T., Meijer, A.J., Groen, A.K., et al. Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation. J. Med. Chem. 53(2), 689-698 (2010).|5. Gupta, V., Hild, S.A., Jakkaraj, S.R., et al. N-Butyldeoxygalactonojirimycin induces reversible infertility in male CD rats. Int. J. Mol. Sci. 21(1), (2020).|6. Kasperzyk, J.L., El-Abbadi, M.M., Hauser, E.C., et al. N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis. J. Neurochem. 89(3), 645-653 (2004).|7. Andersson et al., 2004. Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease. Neurobiology of Disease 16(3):506-515.; Kasperzyk et al., 2004. N‐butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis. J Neurochem 89(3):645-53|8. Paulsen, H., et al.: Chem. Ber., 113, 2601 (1980)|9. Daniel, P.F., et al.: Proc. Int. Carbo. Symp., 13th, Ithaca, NY, Abstr. C43 (1986)USBio References
No references available